Net proceeds are expected to be approximately $4.1 million after offering-related fees and expenses.
Columbia intends to use the net proceeds from the offering for general corporate purposes, including funding its clinical development and other R&D activities, internal and collaborative sales, marketing and distribution expenditures, capital expenditures and working capital needs.